Allergic rhinitis therapeutics pipeline is likely to grow over next few years, on account of increasing air pollution and unchecked exposure of humans to chemicals and radiations, which lead to increase in the incidence of allergic rhinitis. Poor air quality, low market penetration of effective drugs, as most of the available drugs provide temporary relief, and increasing health awareness among people are few other factors expected to propel growth in the allergic rhinitis therapeutics pipeline. According to the latest data published by the American Academy of Allergy, Asthma & Immunology, around 8 percent of adults in the U.S. experience allergic rhinitis. Both males and females are equally susceptible to this disease.
Allergic rhinitis, also known as hay fever, is an allergic response to specific environmental allergens. The most common allergens which causes allergic rhinitis are pollen grains. The symptoms of allergic rhinitis commonly include running nose, coughing, watery eyes, itchy eyes, nose stiffness, headache, dry itchy skin and tiredness. Headache and tiredness are results of prolonged exposure to such allergen. Release of histamine, by the body, is the main cause of allergic rhinitis, when coming in contact with allergens such as grass and dust. The two types of allergic rhinitis include perennial and seasonal. Perennial allergic rhinitis occurs due to dust and mites, while seasonal allergic rhinitis occurs due to pollen grains. Few other factors associated with allergic rhinitis are smoking, exposure to chemicals, air pollution, hair spray, wood smoke, fumes and colognes. Allergic rhinitis is diagnosed by physical examination and certain tests including blood tests, skin prick tests and radioallergosorbent test (RAST). Allergic rhinitis is treated using antihistamines such as allegra, xyzal, zyrtec, clarinex and xyzal, decongestants, eye drops and nasal sprays, immunotherapy and sublingual immunotherapy. Preventing allergic rhinitis can be done by managing allergies to prevent the release of histamine.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/allergic-rhinitis-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of allergic rhinitis therapeutics include ROXALL Medizin GmbH, Stallergenes Greer, Eurofarma Laboratorios S.A., Merck Sharp & Dohme Corp., Astellas Pharma, Inc., Inmunotek S.L., Anergis, GlaxoSmithKline plc, Laboratorios Leti, S.L., Immunomic Therapeutics, Inc., Hanlim Pharm. Co., Ltd., ALK-Abello A/S, Accolade Pharmaceuticals, LLC.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)